27
Participants
Start Date
March 31, 2003
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Gefitinib
Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
National Cancer Institute (NCI)
NIH
Dana-Farber Cancer Institute
OTHER
Brigham and Women's Hospital
OTHER
AstraZeneca
INDUSTRY
Massachusetts General Hospital
OTHER